NEKTAR THERAPEUTICS(NKTR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,916 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
NKTR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for NEKTAR THERAPEUTICS (NKTR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NKTR at 9.7/100 on a 32-signal composite quality model, placing it at rank #2,916 of 2,962 stocks — the bottom half of the AI-ranked universe. NKTR scores in the top quartile across institutional flow (91.9). Areas of concern include free cash flow (2.9) and revenue growth (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NEKTAR THERAPEUTICS reports quarterly revenue of $10.1M, net income of $-40.6M, free cash flow of $-75.9M. Top institutional holders of NKTR by reported 13-F value include FMR, Two Seas Capital, BlackRock, based on the most recent SEC filings. NKTR trades on the Nasdaq exchange and files with the SEC under CIK 906709. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NKTR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEKTAR THERAPEUTICS directly from SEC EDGAR. NEKTAR THERAPEUTICS's 13F Pro composite quality score has ranged between 8 and 17 since 2021, currently 9.7 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$10.1M
Net Income
Q2 2026
$-40.6M
Free Cash Flow
Q2 2026
$-75.9M
ROIC
Q2 2026
-18.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-43.9% YoYNet Income
-37.9% YoYOperating Income
-33.2% YoYEPS (Diluted)
-12.1% YoYTotal Assets
-7.7% YoYOp. Cash Flow
-18.7% YoYFree Cash Flow
-17.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $55.2M -43.9% | $98.4M +9.2% | $90.1M -2.1% | $92.1M -9.7% | $101.9M -33.4% | $152.9M |
| Net Income | $-164.1M -37.9% | $-119.0M +56.9% | $-276.1M +25.0% | $-368.2M +29.7% | $-523.8M -17.9% | $-444.4M |
| Operating Income | $-140.1M -33.2% | $-105.2M +60.1% | $-263.7M +29.9% | $-376.2M +15.7% | $-446.1M -4.9% | $-425.1M |
| EPS (Diluted) | $-9.73 -12.1% | $-8.68 -498.6% | $-1.45 +26.4% | $-1.97 +31.1% | $-2.86 -14.9% | $-2.49 |
| Total Assets | $280.4M -7.7% | $303.9M -23.7% | $398.0M -44.0% | $710.6M -36.4% | $1.12B -27.4% | $1.54B |
| Operating Cash Flow | $-208.5M -18.7% | $-175.7M +8.8% | $-192.6M +36.6% | $-304.0M +26.3% | $-412.7M -31.7% | $-313.3M |
| Free Cash Flow | $-208.7M -17.8% | $-177.2M +8.4% | $-193.5M +37.5% | $-309.7M +27.6% | $-427.6M -33.4% | $-320.5M |
Get alerted when NKTR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NEKTAR THERAPEUTICS including:
Top Institutional Holders of NKTR
FMR LLC
$353.8M5,067,920 shTwo Seas Capital LP
$215.9M3,092,234 shBlackRock, Inc.
$205.4M2,941,851 shBVF INC/IL
$166.9M2,391,075 shVANGUARD CAPITAL MANAGEMENT LLC
$104.5M1,496,849 shTWO SIGMA INVESTMENTS, LP
$83.9M1,202,004 shVestal Point Capital, LP
$69.8M1,000,000 shMORGAN STANLEY
$65.4M936,560 shSTATE STREET CORP
$63.5M909,679 shGEODE CAPITAL MANAGEMENT, LLC
$61.5M881,306 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $353.8M | 5,067,920 |
| Two Seas Capital LP | $215.9M | 3,092,234 |
| BlackRock, Inc. | $205.4M | 2,941,851 |
| BVF INC/IL | $166.9M | 2,391,075 |
| VANGUARD CAPITAL MANAGEMENT LLC | $104.5M | 1,496,849 |
| TWO SIGMA INVESTMENTS, LP | $83.9M | 1,202,004 |
| Vestal Point Capital, LP | $69.8M | 1,000,000 |
| MORGAN STANLEY | $65.4M | 936,560 |
| STATE STREET CORP | $63.5M | 909,679 |
| GEODE CAPITAL MANAGEMENT, LLC | $61.5M | 881,306 |
Companies Similar to NKTR
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
SUTRO BIOPHARMA, INC.
Celldex Therapeutics, Inc.
CytomX Therapeutics, Inc.
Silence Therapeutics plc
Arcus Biosciences, Inc.
ALUMIS INC.
uniQure N.V.
BioAge Labs, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NKTR on your watchlist
Track score changes the day NEKTAR THERAPEUTICS files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NKTR a good stock to buy?
13F Pro's AI-powered analysis of NEKTAR THERAPEUTICS (NKTR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NKTR are available on the NKTR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NKTR is classified as a mid company.
Which hedge funds own NKTR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NKTR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEKTAR THERAPEUTICS's investment landscape.